A recent clinical trial showed that treatment with the Nrf2 antagonist, a specific antioxidant that affects the Prx4 pathway, is an effective intervention against the decline in renal function in patients with chronic kidney disease and type 1 diabetes [15, 43]. Here, NFE2L2 is linked to type 1 diabetes mellitus.